Exela Pharm Sci Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 20-12-2024
- Paid Up Capital ₹ 1.93 Cr
as on 20-12-2024
- Company Age 20 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -4.67%
(FY 2021)
- Profit -38.83%
(FY 2021)
- Ebitda 7.18%
(FY 2021)
- Net Worth 6.58%
(FY 2021)
- Total Assets 7.53%
(FY 2021)
About Exela Pharm Sci
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 1.93 Cr, as per Ministry of Corporate Affairs (MCA) records.
Murali Adala, Saba Ganapathi, and Phanesh Koneru serve as directors at the Company.
- CIN/LLPIN
U24231TG2004PTC125972
- Company No.
125972
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 May 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Exela Pharm Sci?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Murali Adala  | Director | 26-May-2004 | Current |
Saba Ganapathi  | Additional Director | 11-Jul-2016 | Current |
Phanesh Koneru  | Director | 29-Sep-2005 | Current |
Financial Performance of Exela Pharm Sci.
Exela Pharm Sci Private Limited, for the financial year ended 2021, experienced Minor drop in revenue, with a 4.67% decrease. The company also saw a substantial fall in profitability, with a 38.83% decrease in profit. The company's net worth moved up by a moderate rise of 6.58%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Exela Pharm Sci?
In 2021, Exela Pharm Sci had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
M.A.K Projects Private LimitedActive 18 years 8 monthsMurali Adala and Saba Ganapathi are mutual person
- M.A.K Hotels & Resorts Private LimitedActive 17 years 9 months
Murali Adala and Saba Ganapathi are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Exela Pharm Sci?
Unlock and access historical data on people associated with Exela Pharm Sci, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Exela Pharm Sci, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Exela Pharm Sci's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
